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Summary
Stickler and Marshall syndromes are dominantly inher-
ited chondrodysplasias characterized by midfacial hy-
poplasia, high myopia, and sensorineural-hearingdeficit.
Since the characteristics of these syndromes overlap, it
has been argued whether they are distinct entities or
different manifestations of a single syndrome. Several
mutations causing Stickler syndrome have been found
in the COL2A1 gene, and one mutation causing Stickler
syndrome and one causing Marshall syndrome have
been detected in the COL11A1 gene. We characterize
here the genomic structure of the COL11A1 gene.
Screening of patients with Stickler, Stickler-like, or Mar-
shall syndrome pointed to 23 novel mutations. Geno-
typic-phenotypic comparison revealed an association be-
tween the Marshall syndrome phenotype and splicing
mutations of 54-bp exons in the C-terminal region of
the COL11A1 gene. Null-allele mutations in the
COL2A1 gene led to a typical phenotype of Stickler
syndrome. Some patients, however, presented with phe-
notypes of both Marshall and Stickler syndromes.
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Introduction
Stickler syndrome (MIM 108300) is an autosomal dom-
inantly inherited disorder characterized by typical facial,
ocular, articular, and auditory features (Stickler et al.
1965; Stickler and Pugh 1967; Herrmann et al. 1975;
Temple 1989). Frequently, reported findings are high
myopia, vitreoretinal degeneration, retinal detachment,
cleft palate, midfacial hypoplasia, osteoarthritis, and
sensorineural-hearing loss. Very similar features are also
found in Marshall syndrome (MIM 154780; Marshall
1958; Shanske et al. 1997 ), however, and there has been
a continuing debate as to whether these are distinct en-
tities or different manifestations of a single syndrome
(Cohen 1974; Winter et al. 1983; Ayme´ and Preus 1984;
Stratton et al. 1991; Shanske et al. 1997). It has been
suggested that Marshall syndrome differs from Stickler
syndrome in that patients with Marshall syndromemore
often have short stature, deafness, and abnormalities in
cranial ossification and more-pronounced dysmorphic
features, including a retracted midface with flat nasal
bridge, short nose, anteverted nostrils, and a long phil-
trum. In addition, it has been suggested that retinal de-
tachment occurs less frequently in patientswithMarshall
syndrome than in patients with Stickler syndrome
(O’Donnell et al. 1976; Ayme´ and Preus 1984; Stratton
et al. 1991).
The first locus identified in Stickler syndrome was
COL2A1 (Francomano et al. 1987; Knowlton et al.
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1989), the gene that codes for the a1 chain of collagen
II. A large number of mutations have been described in
this gene, which cause various disorders ranging from
early-onset osteoarthritis to lethal chondrodysplasias,
depending on the mutation and its location in the mol-
ecule (Spranger et al. 1994; Vikkula et al. 1994; Kui-
vaniemi et al. 1997). So far, all mutations characterized
in the COL2A1 gene that cause Stickler syndrome lead
to a premature translation-termination codon and thus
to reduced amounts of collagen II (Williams et al. 1996;
Kuivaniemi et al. 1997). This COL2A1 locus was ex-
cluded in several families with Stickler syndrome, how-
ever (Knowlton et al. 1989; Vintiner et al. 1991; Bon-
aventure et al. 1992), and, subsequently, a mutation
resulting in a glycine substitution at a second locus,
COL11A1, was found to be linked to the disease in one
family (Richards et al. 1996). On the other hand, Mar-
shall syndrome was hypothesized to be caused by mu-
tations in the COL11A1 gene which code for the a1
chain of collagen IX (van Steensel et al. 1997). The same
gene was also identified as a locus for Marshall syn-
drome (Griffith et al. 1998). We report here the char-
acterization of the genomic structure of the COL11A1
gene and the screening of a set of patients withMarshall,
Stickler, or Stickler-like syndrome for mutations in the
COL2A1 and COL11A1 genes, to reveal possible cor-
relations between the mutant gene, mutation type, and
phenotype.
Subjects and Methods
Characterizing the Genomic Structure of the COL11A1
Gene
Several PCR primer pairs were designed, on the basis
of the published cDNA sequences for the a1 chain of
collagen XI (Bernard et al. 1988) or of sequences defined
in this study to screen human genomic P1, PAC, and
BAC libraries (Genome Systems, Inc.). The primers used
for screening were from sequences corresponding to 5′-
UTR (5′-GAG TAG GCA GCC GAA TGA GTC and 5′-
GAA AGG AAT TGC AGG AGA GC), introns 4 and
5 (5′-TAA ACC ACA TCT CGC TTT GG and 5′-CAA
AAA CTG CAC TGC TAT GTC C), exons 27 and 28
(5′-GGT CCA CAA GGT CCT ATT GG and 5′-TTT
AGA TCC CTT GAG ACC TCT G), introns 28 and 29
(5′-ATC AGA ATC TGT GGC TGG AG and 5′-CAA
TTG ATA CTA CAC TAT CTC CAC), and introns 52
and 53 (5′-TTT TTG CGG AGA GTG AGA GG and
5′-CAT AGA GCT ATG TTT TTC AAA GGC TG). One
P1, two PAC, and two BAC clones were obtained, and
DNA was isolated according to the manufacturer’s rec-
ommended protocol (Genome Systems, Inc.). To define
the genomic organization and intronic sequences flank-
ing the exons, exon-specific primers based on the cDNA
sequences were used to sequence the clones with an ABI
Prism 377 Sequencer and BigDye or dRhodamine Ter-
minator Cycle Sequencing Ready Reaction Kit (PE Bios-
ystems). Sequencing was performed, either directly from
the clones or by first amplifying one or more introns by
PCR (Expand Long Template PCR System, Boehringer
Mannheim) and then sequencing the PCR products. The
PCR products were purified enzymatically prior to se-
quencing (Werle et al. 1994). The sizes of the introns
were determined by sequencing or estimation on agarose
gel. When the size of the intron was determined by PCR
amplification two different pairs of primers were used,
or the ends of the PCR products were sequenced to rule
out nonspecific amplification.
Subjects
The study reported here began with a group of 30
patients who were referred to us with suspected diag-
noses of Marshall or Stickler syndrome. They were an-
alyzed for mutations in the COL11A1 and COL2A1
genes. Mutations were found in 23 of the patients. The
referring physicians for these 23 patients were then asked
to provide complete clinical data, to substantiate their
diagnoses of either Marshall or Stickler syndrome.
Mutation Analysis of the COL11A1 and COL2A1
Genes
Genomic DNA was extracted from blood leukocytes,
and conformation-sensitive gel electrophoresis (CSGE)
was used to scan the exons and exon boundaries in the
COL11A1 and COL2A1 genes for mutations (Ganguly
et al. 1993; Ko¨rkko¨ et al. 1998). PCR primers were
designed for the COL11A1 gene on the basis of the
sequences defined here, and, for the COL2A1 gene, on
the basis of the sequences published in the article by Ala-
Kokko et al. (1995). The PCR products were 188–500
bp in size and contained60 bp of the sequence flanking
the target sequence, at both ends. The PCR reactions
were performed in a 40-ml vol with 50–200 ng of ge-
nomic DNA, 0.25 mM of both primers, 1.5 mM MgCl2,
0.2 mM dNTPs, and 1 U AmpliTaq Gold polymerase
(PE Biosystems). The conditions, after the initial dena-
turation at 95C for 10 min, were 35 cycles of 30 s at
95C, 30 s at 50–63C, and 30 s at 72C, followed by
a final extension at 72C for 5 min. The PCR products
were denatured at 98C for 3 min, followed by annealing
at 68C for 30 min, at the end of the PCR cycling, to
generate the heteroduplexes essential to CSGE analysis.
A 5-ml aliquot of the reaction mixture was analyzed on
an agarose gel, to check the quality and quantity of the
PCR products and to reveal possible large deletions or
insertions.
From 40–100 ng of the PCR product was mixed with
a loading buffer consisting of xylene cyanol FF, brom-
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Figure 1 Schematic presentation of the genomic organization of the COL11A1 gene and the genomic clones covering the gene, drawn
to scale. The clone addresses are BACH-86N5 (1), DMPC-HFF#1-140(B10) (2), PAC-154-1M (3), PAC 84:8A (4), and 170O21 (5).
phenol blue, and 30% glycerol and was loaded onto the
CSGE gel. The gel composition was 10%–15% 1,4-bis-
acryloylpiperazine acrylamide, 99:1 ratio of acrylamide
to 1,4-bis-acryloylpiperazine (Fluka), 15% formamide,
10% ethylene glycol, 0.1% ammonium persulfate, and
0.07% N,N,N,N-tetramethylethylenediamine in 0.5 #
TTE buffer (44.4 mM Tris–14.25 mM Taurine–0.1 mM
EDTA). The gel was electrophoresed on a standard se-
quencing apparatus at 40–45 W for 5–8 h with 0.5#
TTE as the electrode buffer. After electrophoresis, the
gel was stained with ethidium bromide and was pho-
tographed. The PCR products that contained hetero-
duplexes (i.e., multiple bands on CSGE analysis) were
sequenced to define their sequence variations.
RT-PCR Analysis of Splicing Mutations
Total RNA was extracted from cultured skin fibro-
blasts (RNeasy Midi Kit, Qiagen) and 5 mg was used
as a template for first-strand synthesis (Superscript
Preamplification System, Gibco BRL) performed with
oligo(dT) primer, under the conditions suggested by the
manufacturer for transcripts with high GC content. The
subsequent PCR amplifications of illegitimate transcripts
were performed with the a1(XI) cDNA-specific primers,
and the products were sequenced.
Results
Characterization of the Human COL11A1 Gene
Altogether, five P1, PAC, or BAC clones, covering the
majority of the human COL11A1 gene, were obtained
with the probes (fig. 1). The human COL11A1 gene was
1150 kb in size and consisted of 68 exons (table 1).
More than 50,000 bp of new sequences were defined for
the gene (GenBank accession numbers AF101079–
AF101112). All splice sites in the COL11A1 gene were
conventional. The exons were numbered 1–67 (table 1),
with numbers 6A and 6B used for the sixth and seventh
exons (previously called IIA and IIB) because they are
alternatively spliced and do not exist in the same mRNA
(Zhidkova et al. 1995). Exons numbered 9–15 by Ber-
nard et al. (1988) correspond to exons 16–22 in this
numbering.
Resequencing of the coding region indicated some dif-
ferences relative to the published cDNA sequence (Ber-
nard et al. 1988). No cysteinyl residue was found in the
triple-helical region, and the amino acid sequence at
amino acid positions (aa) 413–416, calculated from the
first glycine of the main triple-helical domain, was Lys-
Asp-Gly-Leu instead of Arg-Met-Gly-Cys. In addition,
the amino acid at aa 690 was methionine instead of
tryptophan, an amino acid rarely found in collagen triple
helices. These sequences were verified in 150 alleles.
Mutation Analysis
Patients with Marshall, Stickler, or Stickler-like syn-
drome were screened for mutations in the COL11A1
gene. The exons and exon boundaries of the gene (except
for exons 2 and 4) were amplified, denaturated, and
reannealed to generate heteroduplexes and were ana-
lyzed on agarose gel, followed by CSGE analysis. The
agarose-gel analysis of the PCR products for exon 53
suggested a heterozygous deletion of ∼150 bp in one
patient (data not shown). Sequencing indicated that the
deletion was 162 bp and that it contained 85 bp of IVS52
exon 53 and 23 bp of IVS53 (table 2). The deletion was
likely to result from a nonhomologous recombination
event, since there was little junctional homology (Hen-
thorn et al. 1990; Helleday et al. 1998). In addition,
several unique sequence variations were observed on
CSGE (data not shown). Sequencing identified 10 mu-
tations altering the conventional splicing-consensus se-
quences, two small in-frame deletions in the coding se-
quences, and two glycine substitutions (table 2).
The COL2A1 gene was screened for mutations in the
patients for whom no mutations were found in the
COL11A1 gene. CSGE analysis and sequencing identi-
fied eight novel mutations altogether in the COL2A1
gene (data not shown), six causing a frameshift leading
to premature translation-termination codons (in patients
17–19 and in patients 21–23; table 2) and two altering
the splicing-consensus sequences (in patients 16 and 20;
table 2). The mutations cosegregated with the pheno-
types in all familial cases (table 3).
RT-PCR
Patient 5 had an ArC change at aa 3 in the IVS50
of the COL11A1 gene. To study the effect of this se-
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Table 1
Sizes of the Exons and Introns of the Human COL11A1
Gene
No. of Exon Size of Exon (in bp) Size of Intron (in bp)
1 106 ND
2 168 ∼4,000
3 214 ∼4,000
4 163 ND
5 129 ∼4,500
6Aa 117 263
6Ba 153 186
7 93 ∼2,500
8b 255 972
9 63 ∼3,000
10 42 935
11 63 ∼2,000
12 75 1,073
13 84 ∼2,000
14c 57 ∼4,000
15 54 ∼2,000
16d 54 152
17d 54 173
18d 54 1,176
19d 54 119
20d 45 1,174
21d 54 423
22d 45 265
23 54 458
24 45 ∼3,500
25 54 1,184
26 45 1,038
27 54 80
28 45 ∼6,000
29 54 ∼2,000
30 108 ∼3,500
31 54 ∼4,500
32 54 277
33 45 146
34 54 107
35 45 ∼3,500
36 54 ∼3,500
37 54 ∼4,500
38 54 ∼2,500
39 108 390
40 90 256
41 54 ∼14,000
42 108 ∼6,500
43 108 1,240
44 54 ∼4,000
45 54 503
46 108 ∼11,000
47 54 ∼1,500
48 54 1,154
49 54 ∼4,500
50 54 816
51 108 299
52 54 661
53 54 1,424
54 54 ∼12,000
55 54 167
56 108 487
57 54 ∼7,500
(continued)
Table 1 (continued)
No. of Exon Size of Exon (in bp) Size of Intron (in bp)
58 54 888
59 108 545
60 54 107
61 36 92
62 54 ∼1,500
63c 250 ∼3,500
64 113 ∼1,500
65 69 ∼2,000
66 234 ∼1,500
67 147 )
NOTE.—ND denotes not determined.
a Previously were called exons IIA and IIB (Zhidkova et al.
1995), and are alternatively spliced exons (Zhidkova et al.
1995).
b Alternatively spliced exons (Zhidkova et al. 1995).
c Junction exons.
d Exons 16–22 were previously numbered 9–15 (Bernard et
al. 1988).
quence variation on splicing, RT-PCR analysis for ille-
gitimate mRNA transcripts, extracted from the patient’s
cultured skin fibroblasts, was performed. Two PCR
products were obtained, one corresponding to the wild-
type cDNA sequence and one lacking the sequences for
exon 50 (data not shown).
Patient 6 had a T insertion at aa3 in the IVS50. No
RNA was available, but DNA was obtained from the
parents of the patient—who were unaffected—and an-
alyzed for the sequence variation. Neither parent had
the insertion.
Genotypic-Phenotypic Comparison
All the COL11A1 mutations were found in the region
coding for the major triple-helical domain, the majority
(10 of 15) altering the splicing-consensus sequences. All
of these mutations occurred in the splicing-consensus
sequences of 54-bp exons (tables table 1 and 2). Eight
of the mutations were located in exons 48–54, and four
of them were located in exon 50. The analysis also iden-
tified two glycine substitutions and three in-frame de-
letions in exons 53 (54 bp), 36 (18 bp), and 52 (9 bp).
These mutations were not equally distributed through-
out the gene. Only one mutation altering the splicing-
consensus sequence and one glycine substitution were
located in the N-terminal third of the triple helix.
To evaluate the phenotypic consequences of the
COL11A1 and COL2A1 gene mutations, the patients
were evaluated clinically, with particular focus on the
major findings in the Stickler and Marshall syndromes,
especially the characteristics reported to differ between
these syndromes (O’Donnell et al. 1976; Ayme´ and
Preuss 1984; Stratton et al. 1991). In general, the phe-
notypes caused by the mutations in the COL11A1 and
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Table 2
Mutations Detected in the COL11A1 and COL2A1 Genes
Patient Gene Mutation
1 COL11A1 T2IVS38rC
2 COL11A1 G1IVS38rT
3 COL11A1 A2IVS43rG
4 COL11A1 A2IVS47rG
5 COL11A1 A3IVS50rC
6 COL11A1 InsT3IVS50
7 COL11A1 G1IVS50rC
8 COL11A1 4-bp deletion in E50/IVS50 (the last 3 bp of E50 and the 1st bp of IVS50)
9 COL11A1 Deletion from 85IVS52 to 23IVS53
10 COL11A1 G1IVS54rA
11 COL11A1 DelA2IVS14
12 COL11A1 G148R
13 COL11A1 18-bp deletion in E36 (aa 393–398)
14 COL11A1 9-bp deletion in E52 (aa 785–787)
15 COL11A1 G988V
16 COL2A1 G1IVS12rA
17 COL2A1 Deletion of nt 10,819 (T) in E13
18 COL2A1 E506X in E31
19 COL2A1 Deletion of nt 22,620 (C) in E34
20 COL2A1 G1IVS39rT
21 COL2A1 25-bp deletion (nt 25,715– 25,739) in E40
22 COL2A1 Deletion of nt 28,829 in E49
23 COL2A1 Deletion of nt 29,616 in E50
COL2A1 genes resembled each other (table 3). The clin-
ical findings of the patients who had a mutation in either
of the genes typically consisted of highmyopia,midfacial
hypoplasia, palatal defects, and micro/retrognathia.
Hearing deficit and osteoarthritis were also relatively
common findings. There were some major differences,
however. The vast majority of patients with COL11A1
mutations had moderate-to-severe hearing impairment
that was congenital or was detected in early childhood,
whereas the patients with COL2A1 mutations had nor-
mal hearing or minor hearing loss that usually developed
later in life. The ocular findings were generally more
severe in the patients with COL2A1 mutations than in
those with COL11A1 mutations, in that almost all pa-
tients with the former had vitreoretinal degeneration and
retinal detachment. Furthermore, cataracts were more
common in patients with COL2A1 mutations than in
the patients with COL11A1 mutations. As indicated in
table 3, slight differences were also seen in stature and
facial characteristics. Figure 2 presents differences of fa-
cial characteristics caused by COL2A1 and COL11A1
mutations. In Marshall syndrome, midfacial hypoplasia,
short nose, and flat nasal bridge were more clearly pro-
nounced and did not disappear when the child aged.
Osteoarthritic changes could not be evaluated, because
many of the patients were too young to be evaluated for
such changes. Cranial radiographs were available for
only six patients/families with COL11A1 mutations and
for only twowith COL2A1mutations. None of the latter
showed cranial abnormalities, whereas four out of the
six in the former group had abnormalities such as ab-
normal frontal sinuses, intracranial calcifications, and/
or a thickened calvarium.
The patients with COL11A1 and COL2A1 mutations
could be divided into two groups on the basis of the
phenotype and mutational type (table 4). The first group
(patients 1–10) had a splicing mutation in a 54-bp exon
in the COL11A1 gene region coding for the C-terminal
half of the a1(XI) molecule, and their characteristics
resembled those reported in Marshall syndrome (Ayme´
and Preus 1984; Shanske et al. 1997; Griffith et al.
1998). The second group (patients 16–23) had a mu-
tation in the COL2A1 gene and a phenotype that more
closely resembled classic Stickler syndrome (Stickler et
al. 1965; Stickler and Pugh 1967; Herrmann et al. 1975).
Patients 11–15 had other mutations in the COL11A1
gene and phenotypes overlapping those of bothMarshall
and Stickler syndrome (table 3).
Discussion
In the course of this work we defined the structure of
the COL11A1 gene and 150 kb of new sequences for
it, and used the sequences to develop a mutation-screen-
ing procedure. Patients with Marshall, Stickler, or Stick-
ler-like syndrome were then screened for mutations in
the COL11A1 and COL2A1 genes, and 15 novel mu-
tations in the former and 8 in the latter were identified.
The majority of the mutations in the COL11A1 gene
altered the splicing-consensus sequences, with all of them
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Table 3
Clinical Findings
FINDINGS
PATIENT NUMBERa
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Age (years)b 6 F 10 3 27 28 4 F 2 38 F F 17 5 Fc 2 9 F F 24 Fd F F
Hearing loss 7                  e e  e
Retinal
detachment                       
Vitreoretinal
degeneration                     
Cataract f                     
High myopia                       
Short stature                      
Tall stature                      
Hypertelorism                     
Epicanthus                   
Short nose                      
Anteverted nares                     
Micro/retrognathia                     
Midfacial
hypoplasia                      
Flat nasal bridge                      
Long philtrum                    
Palatal defect                       
Lowered auricles               
Dental
abnormalities               
Abnormal frontal
sinuses      
Intracranial
ossifications       
Thick calvarium        
NOTE.—A plus sign (“”) denotes presence of the finding, and a minus sign (“”) denotes the absence of the finding.
a Patients showed a splicing mutation of a 54-bp exon, or showed a genomic deletion causing a loss of 54 bp in exons coding for the C-
terminal half of the a1(XI) molecule (patients 1–10), other mutations in the COL11A1 gene (patients 11–15), and the mutation in the COL2A1
gene (patients 16–23). Osteoarthritic changes were not evaluated because many of the patients were too young.
b An “F” denotes that several affected family members were evaluated and the results were combined.
c The clinical features of case 15 (family B) have been published previously by Zlotogora et al. (1992).
d The clinical features of case 21 (family DP-Minn) have been published previously by Knowlton et al. (1989).
e Presented with a mild hearing defect.
f Presented with cataract later in life.
affecting the splicing-consensus sequences of 54-bp ex-
ons, as was reported by Griffith et al. (1998). In addition,
one patient had a genomic deletion resulting in the loss
of a 54-bp exon. Nine out of ten of these mutations
affected the splicing of 54-bp exons in a region spanning
exons 38–54 of the gene. Although more than one-third
of the exons in this region are 90 or 108 bp in size, no
splicing mutations were found in them. Six of the
COL2A1 gene mutations resulted in a premature trans-
lation-termination codon, and two of the mutations al-
tered the splicing-consensus sequences. These two pa-
tients (patients 16 and 20) had features typical of Stickler
syndrome, with no signs of more-severe chondrodyspla-
sias such as spondyloepiphyseal dysplasia or Kniest dys-
plasia. For this reason, it is likely that the mutations in
the splicing-consensus sequences lead to cryptic splice
sites and thus to premature translation-termination co-
dons, as was reported in the original Stickler kindred
(Williams et al. 1996).
Our patients with a COL2A1 mutation had a phe-
notype that has frequently been described, in Stickler
syndrome, as caused by COL2A1 mutations leading to
a premature translation-termination codon (Brown et al.
1993; Williams et al. 1996; Kuivaniemi et al. 1997). The
phenotype of the patients with COL11A1 mutations dif-
fered from this to some extent. One major difference
was that, with only one exception, they had early-onset
hearing loss and required hearing aids, whereas the pa-
tients with COL2A1 mutations had normal hearing or
only slight hearing impairment. There were also differ-
ences in ocular findings. Although almost all of the pa-
tients with COL2A1 mutations had vitreoretinal degen-
eration and retinal detachment, those with COL11A1
mutations seldom showed such eye findings. Even
Figure 2 Facial features of patient 16 (A and B), clinically diagnosed with Stickler syndrome, and patients 7 (C and D) and 6 (E and F),
clinically diagnosed with Marshall syndrome.
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Table 4
Summary of the Clinical Data
Findings
COL11A1
Mutations
(Patients 1–10)a
COL2A1
Mutations
(Patients 16–23)
Hearing loss 10/10 0/7b
Retinal detachment 1/10 6/8
Vitreoretinal degeneration 3/9 5/7
Cataract 4/10 5/7
High myopia 10/10 8/8
Short stature 6/10 2/7
Tall stature 0/10 2/7
Hypertelorism 6/10 2/7
Epicanthus 7/9 3/5
Short nose 10/10 5/7
Anteverted nares 10/10 3/6
Micro/retrognathia 8/10 4/6
Midface hypoplasia 10/10 7/7
Flat nasal bridge 10/10 6/7
Long philtrum 7/9 4/6
Palate defect 8/10 8/8
Lowered auricles 4/8 1/4
Dental abnormalities 1/9 1/3
Abnormal frontal sinuses 2/3 0/2
Intracranial ossifications 1/3 0/2
Thick calvarium 2/4 0/2
a Patients with splicing mutation of a 54-bp exon or with a
genomic deletion causing a loss of 54 bp in exons coding for the
C-terminal half of the a1(XI) molecule.
b Three cases presented with minor hearing deficit.
though cranial radiographs were available for only eight
patients, the findings suggest that cranial abnormalities
are common in cases with COL11A1 mutations.
Collagens II and XI are expressed in hyaline cartilage,
in the ocular vitreous, and in the nucleus pulposus of
the intervertebral disc (Kielty et al. 1993; Prockop and
Kivirikko 1995), and are also found in the inner ear
(Slepecky et al. 1992). Collagen XI is a quantitatively
minor collagen associated with homotrimers of collagen
II. It is a heterotrimer of three genetically distinct a
chains, a1(XI), a2(XI), and a3(XI). The a1(XI) and
a2(XI) chains are encoded by the COL11A1 and
COL11A2 genes, and the third chain is a posttransla-
tionally modified variant of the COL2A1 gene product
(Eyre and Wu 1987). Because of the structural and func-
tional similarities, it is not surprising that COL2A1 and
COL11A1 mutations lead to similar phenotypes.
COL11A2 mutations have been shown to cause oto-
spondylomegaepiphyseal dysplasia (Vikkula et al. 1995),
Weissenbacher-Zweymu¨ller syndrome (Pihlajamaa et al.
1998) and Stickler-like syndrome (Vikkula et al. 1995;
Sirko-Osadsa et al. 1998), the phenotypes that overlap
with Stickler and Marshall syndromes but that are de-
void of ocular involvement. The a2(V) chain substitutes
for the a2(XI) chain in the vitreous (Mayne et al. 1993),
thus explaining the lack of the ocular symptoms in pa-
tients with the COL11A2 gene mutations
Our results indicate that patients with a splicing mu-
tation in a 54-bp exon or with a mutation causing a 54-
bp deletion in the C-terminal half of the COL11A1 gene
more frequently showed with findings related to Mar-
shall syndrome, and the mutations in the COL2A1 gene
leading to a premature translation-termination codon
caused the more classic Stickler syndrome phenotype.
The genotype-phenotype correlation detected here sup-
ports the old clinical suspicion of two separate entities.
However, other mutations in the COL11A1 gene re-
sulted in overlapping phenotypes of Marshall and Stick-
ler syndromes, possibly explaining the conflicting reports
of whether Stickler andMarshall syndromes are separate
entities.
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